BOSTON, April 9, 2025 -- Solu Therapeutics, a biotechnology company pioneering therapies to eliminate disease-driving cells in cancer, immunology, and other therapeutic areas, today announced the successful completion of a $41 million Series...
Balance Therapeutics is a clinical-stage pharmaceutical company developing therapies to improve the lives of patients with debilitating neurological conditions. The company focuses on areas of high unmet medical need where neurobiological pathways provide a strong rationale for our pharmacological approach. Balance's experienced drug development team is committed to advancing products to deliver life-improving medicines that serve patients and their families. The company's principal areas of focus are sleep disorders and cognitive deficits.
© 2025 Pappas Capital, LLC. ALL RIGHTS RESERVED.